Abatacept Research Outcome as a First-line Biological Agent in the Real World

Abatacept Research Outcome as a First-line Biological Agent in the Real World - ABROAD study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004651

Enrollment

100

Registered

2010-12-06

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Meet the criteria for Post Marketing Surveillance in Japan. 2) Biologic Naive. 3) Stable low dose of corticosteroids (<=10mg per day)at least 28 days before enrollment.

Exclusion criteria

Exclusion criteria: Patients who are inadequate by investigator's decision.

Design outcomes

Primary

Measure	Time frame
The proportion of subjects in remission(2010 ACR/EULAR new RA remission criteria. DAS28-CRP<2.3) (48 Weeks)	—

Secondary

Measure	Time frame
Persistence rate Stratified analysis of remission rate (in each disease duration) Change in HAQ Change in Anti-CCP2 X-ray	—

Countries

Japan

Contacts

Public ContactHajime Sano

Department of Internal Medicine, Hyogo College of Medicine Division of Rheumatology

hsano@hyo-med.ac.jp0798-45-6592

Outcome results